

11 September 2025

Convatec Group Plc
("Convatec" or "the Company")

Director/ PDMR Shareholding

The Company has been notified of the following transactions in relation to Persons Discharging Managerial Responsibility ("PDMR") under the Convatec 2017 Save as You Earn share option scheme (the "SAYE Scheme") in respect of ordinary shares of 10 pence each in the Company ("Shares").

Grant of SAYE options

On 10 September 2025, options were granted to Jonny Mason, Interim Chief Executive Officer, and Fiona Ryder, Interim Chief Financial Officer, over a total of 18,6860 ordinary shares of 10 pence each in the Company ("Shares") at an option price of 196.46 pence per share under the SAYE Scheme. The options will become exercisable in the ordinary course from 1 September 2028.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated						
a)	Name	Jonny Mason					
2	Reason for the notification						
a)	Position/status	Interim Chief Executive Officer and PDMR					
b)	Initial notification /Amendment	Initial Notification					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Convatec Group Plc					
b)	LEI	213800LS272L4FIDOH92					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument	Ordinary share of 10p each in Convatec Group Plc					
	Identification code	GB00BD3VFW73					
b)	Nature of the transaction	Grant of options under the Convatec Group PLC 2017 Save As You Earn Scheme					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£1.9646</td><td>9,340</td></tr></table>		Price(s)	Volume(s)	£1.9646	9,340
Price(s)	Volume(s)						
£1.9646	9,340						
d)	Aggregated information						
	- Aggregated volume	N/A - single transaction					
	- Price						
e)	Date of the transaction	10 September 2025					
f)	Place of the transaction	Outside a trading venue					

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Fiona Ryder
2	Reason for the notification	

2	Reason for the notification					
a)	Position/status	Interim Chief Financial Officer and PDMR				
b)	Initial notification /Amendment	Initial Notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Convatec Group Plc				
b)	LEI	213800LS272L4FIDOH92				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Ordinary share of 10p each in Convatec Group Plc GB00BD3VFW73				
b)	Nature of the transaction	Grant of options under the Convatec Group PLC 2017 Save As You Earn Scheme				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£1.9646</td><td>9,340</td></tr></table>	Price(s)	Volume(s)	£1.9646	9,340
Price(s)	Volume(s)					
£1.9646	9,340					
d)	Aggregated information - Aggregated volume - Price	N/A - single transaction				
e)	Date of the transaction	10 September 2025				
f)	Place of the transaction	Outside a trading venue				

Enquiries

James Kerton Company Secretary

Tel: +44 (7827) 036059

Email: cosec@convatec.com

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over 2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit <http://www.convatecgroup.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLFIRATILLIE